Clinical development directions in oncolytic viral therapy

被引：97

作者：

Eager, R. M. ^{[1
]}

Nemunaitis, J. ^{[1
,2
,3
]}

机构：

[1] Univ Hawaii, Mary Crowley Canc Res Ctr, Dept Internal Med, Dallas, TX 75201 USA

[2] Texas Oncol PA, Dallas, TX USA

[3] Med City Dallas Hosp, Dallas, TX USA

来源：

CANCER GENE THERAPY | 2011年 / 18卷 / 05期

关键词：

oncolytic viruses; virotherapy; adenoviruses; herpes simplex virus; HERPES-SIMPLEX-VIRUS; NEWCASTLE-DISEASE-VIRUS; PHASE-I TRIAL; REPLICATION-SELECTIVE ADENOVIRUS; ACTIVE SPECIFIC IMMUNOTHERAPY; SITU CANCER VACCINATION; INCREASES GENE-TRANSFER; SENECA VALLEY VIRUS; ANTITUMOR-ACTIVITY; VACCINIA VIRUS;

D O I：

10.1038/cgt.2011.7

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 [微生物学]; 090105 [作物生产系统与生态工程];

摘要：

Oncolytic virotherapy is an emerging experimental treatment platform for cancer therapy. Oncolytic viruses are replicative-competent viruses that are engineered to replicate selectively in cancer cells with specified oncogenic phenotypes. Multiple DNA and RNA viruses have been clinically tested in a variety of tumors. This review will provide a brief description of these novel anticancer biologics and will summarize the results of clinical investigation. To date oncolytic virotherapy has shown to be safe, and has generated clinical responses in tumors that are resistant to chemotherapy or radiotherapy. The major challenge for researchers is to maximize the efficacy of these viral therapeutics, and to establish stable systemic delivery mechanisms. Cancer Gene Therapy (2011) 18, 305-317; doi:10.1038/cgt.2011.7; published online 25 March 2011

引用

页码：305 / 317

页数：13

共 213 条

[1]

AEROSOL STABILITY OF INFECTIOUS AND POTENTIALLY INFECTIOUS REOVIRUS PARTICLES [J].

ADAMS, DJ ;

SPENDLOVE, JC ;

SPENDLOVE, RS ;

BARNETT, BB .

APPLIED AND ENVIRONMENTAL MICROBIOLOGY, 1982, 44 (04) :903-908

[2]

Advani SJ, 1999, CANCER RES, V59, P2055

[3]

Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumors [J].

Advani, SJ ;

Sibley, GS ;

Song, PY ;

Hallahan, DE ;

Kataoka, Y ;

Roizman, B ;

Weichselbaum, RR .

GENE THERAPY, 1998, 5 (02) :160-165

[4]

Aghi M, 1999, CANCER RES, V59, P3861

[5]

Gene therapy for gliomas:: Molecular targets, adenoviral vectors, and oncolytic adenoviruses [J].

Alemany, R ;

Gomez-Manzano, C ;

Balagué, C ;

Yung, WKA ;

Curiel, DT ;

Kyritsis, AP ;

Fueyo, J .

EXPERIMENTAL CELL RESEARCH, 1999, 252 (01) :1-12

[6]

Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter [J].

Alonso, Marta M. ;

Gomez-Manzano, Candelaria ;

Bekele, B. Nebiyou ;

Yung, W. K. Alfred ;

Fueyo, Juan .

CANCER RESEARCH, 2007, 67 (24) :11499-11504

[7]

The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors [J].

Andreansky, SS ;

He, B ;

Gillespie, GY ;

Soroceanu, L ;

Markert, J ;

Chou, J ;

Roizman, B ;

Whitley, RJ .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (21) :11313-11318

[8]

[Anonymous], MONOGR VIROL

[9]

ARKENAU H, 2009, J CLIN ONCOL S, V27, pNI414

[10]

ASADA T, 1974, CANCER, V34, P1907, DOI 10.1002/1097-0142(197412)34:6<1907::AID-CNCR2820340609>3.0.CO

← 1 2 3 4 5 6 7 8 9 10 →